Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Short Interest Update

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) was the target of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 21,287 shares, an increase of 177.5% from the May 14th total of 7,671 shares. Approximately 11.2% of the company’s shares are sold short. Based on an average daily trading volume, of 7,366 shares, the short-interest ratio is currently 2.9 days.

Bitwise MARA Option Income Strategy ETF Stock Performance

Bitwise MARA Option Income Strategy ETF stock traded up $0.11 during trading on Friday, reaching $17.02. 210 shares of the company’s stock were exchanged, compared to its average volume of 5,322. The company’s 50-day moving average is $16.13 and its two-hundred day moving average is $15.93. Bitwise MARA Option Income Strategy ETF has a 52-week low of $11.99 and a 52-week high of $54.94. The firm has a market cap of $3.23 million, a price-to-earnings ratio of 340.40 and a beta of 2.88.

Insiders Place Their Bets

In related news, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the sale, the director directly owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Helen Louise Collins sold 5,000 shares of the company’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $47.67, for a total transaction of $238,350.00. Following the sale, the insider directly owned 25,000 shares of the company’s stock, valued at approximately $1,191,750. This trade represents a 16.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 60,000 shares of company stock valued at $2,126,550. Insiders own 37.30% of the company’s stock.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.